ORIGINAL RESEARCH article

Front. Med.

Sec. Family Medicine and Primary Care

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1574022

This article is part of the Research TopicOptimizing the Therapeutic Potential in Clinical Settings: Leveraging Placebos and Mitigating Nocebo EffectsView all 9 articles

A Dose of Doubt: A Qualitative Study on Placebo Regulations

Provisionally accepted
  • University of Basel, Basel, Switzerland

The final, formatted version of the article will be published soon.

Introduction: Placebo use is common in primary care, yet ethical and legal concerns persist, and few qualitative studies have explored physicians’ views on placebo regulation. Methods: We conducted semi-structured interviews with ten primary care physicians from two German-speaking Swiss cantons to explore their definitions of placebos, usage in clinical practice, knowledge of existing regulations, and attitudes toward potential regulatory frameworks. Participants were recruited from a publicly available physician registry, yielding a 4.9% response rate. Results: Participants consistently reported using at least impure placebos in their practice, while references to the use of pure placebos were relatively uncommon. A distinction between pure and impure placebos emerged, with the latter generally viewed as more ethically acceptable. Risk-benefit evaluation was emphasized as the primary justification for placebo use. Most participants had not actively sought legal information, and knowledge about current regulations varied considerably. While clear support for specific regulation was rare, most participants did not perceive it as necessary, often citing distrust in regulatory systems or concerns that formal rules could restrict therapeutic flexibility. Expert bodies such as the Swiss Medical Association were mentioned as potential sources of guidance. Discussion: The findings highlight a practice-oriented, risk-benefit-driven approach to placebo use, shaped by skepticism toward regulation and limited legal awareness. Despite frequent use, physicians operate in a legally ambiguous space and express limited demand for regulatory clarity, suggesting a need for targeted professional discourse rather than strict formal regulation.

Keywords: Placebo use, Primary care physicians, clinical decision-making, Healthcare regulation, Medical Ethics

Received: 10 Feb 2025; Accepted: 23 May 2025.

Copyright: © 2025 Richard, Ganz, Elger and Gaab. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Mélina Richard, University of Basel, Basel, Switzerland

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.